compared 45 percent historical control patients 18 months 23 percent patients arm study alive 18 months duke researchers small group poliovirus patients began signs extended survival years follow 21 percent poliovirus patients remained alive compared 14 percent control patients years survival gap widened 21 percent poliovirus patients alive compared 4 percent controls similar immunotherapies appears patients not respond reason respond long term survivors said desjardins patent poliovirus therapy owns stock options istari oncology company seeking commercialize treatment researchers point unable identify advance patients respond group called long tail survivors group long term survivors small raises questions findings reliability years 61